{
  "id": 7604617,
  "title": "Drug Combo's Response Rates Top 90% in Small Cell Lung Cancer Trial",
  "url": "https://urgent.news/2026/09/15/drug-combos-response-rates-top-90-in-small-cell-lung-cancer-trial",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-15T18:01:54.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/meetingcoverage/iaslc/123009"
  },
  "original_language": "en",
  "account": null,
  "summary": "(MedPage Today) -- Up to 90% of patients with advanced small cell lung cancer (SCLC) responded to a PD-L1/VEGF bispecific antibody linked to an antibody-drug conjugate (ADC), a preliminary trial showed. Response rates ranged from 52.4% in patients...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "MedPage Today",
        "title": "Novel Drug Cuts Risk for Death by 44% in Squamous Lung Cancer Trial",
        "url": "https://urgent.news/2026/09/15/novel-drug-cuts-risk-for-death-by-44-in-squamous-lung-cancer-trial",
        "published": "2026-09-15T19:51:17.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}